Skip to content

Study · Systematic review · 2017

3 results

Comparative efficacy of five long-term weight loss drugs: quantitative information for medication guidelines.

Dong Z, Xu L, Liu H, Lv Y, Zheng Q, Li L

Obesity reviews : an official journal of the International Association for the Study of Obesity10 Oct 2017Cited by 37 (Europe PMC)

PMID29024559 (opens in a new tab)DOI10.1111/obr.12606 (opens in a new tab)PepBankPUB-29024559
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In a model-based analysis of weight-loss trials, liraglutide reduced body weight by a maximal 5.50 kg more than placebo, reached at week 65.

    In plain wordsIn weight-loss trials, people on liraglutide lost up to 5.50 kg more than people on placebo, at about week 65.

    Peptide
    Liraglutide
    Outcome
    DecreaseMaximal body weight loss versus placebo
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    maximal efficacy
    −5.5 kg
    liraglutide, week 65

    Source sentences

    Summary
    the maximal efficacies (95% CI) of orlistat (120 mg), lorcaserin, naltrexone-bupropion, phentermine-topiramate (PT, 7.5/46 mg) and liraglutide were -2.94 (-5.82, -1.27), -3.06 (-4.39, -1.71), -6.15 (-9.78, -3.25), -7.45 (-9.76, -3.88) and -5.50 (-10.62, -2.97) kg at weeks 60, 54, 67, 59 and 65 respectively
    1 context sentence
    Summary · context
    Finally, 50 reports (involving 43,443 participants) were included.
  2. 02HumanSystematic reviewEfficacy outcome

    In a model-based analysis of weight-loss trials, body weight regain after the maximal effect of liraglutide was 0.43 kg per year.

    In plain wordsIn weight-loss trials, people on liraglutide regained weight at about 0.43 kg per year after the largest weight loss.

    Peptide
    Liraglutide
    Outcome
    Not applicableRate of body weight regain after maximal efficacy
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    rate of body weight regain
    0.43 kg per year
    liraglutide

    Source sentences

    Summary
    their rates of body weight regain were 0.51, 0.48, 0.91, 1.27and 0.43 kg per year respectively.
    1 context sentence
    Summary · context
    Finally, 50 reports (involving 43,443 participants) were included.
  3. 03HumanSystematic reviewSafety outcome

    In a model-based analysis of weight-loss trials, the 1-year dropout rate with liraglutide was 24.3%.

    In plain wordsIn weight-loss trials, 24.3% of people on liraglutide dropped out within one year.

    Peptide
    Liraglutide
    Outcome
    Not applicable1-year dropout rate
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Measurements

    1-year dropout rate
    24.3%
    liraglutide

    Source sentences

    Summary
    The 1-year dropout rates of orlistat, lorcaserin, naltrexone-bupropion, PT and liraglutide were 29.0, 40.9, 49.1, 34.9 and 24.3% respectively.
    1 context sentence
    Summary · context
    Finally, 50 reports (involving 43,443 participants) were included.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.